Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence